Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL-18 suppository in vulvovaginal candidiasis
CTR20232467Phase 2Active
- Sponsor
- Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
- Start
- Sep 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of PL-18 in vulvovaginal candidiasis (VVC), sponsored by Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.. Started Sep 2023; status: active.
02
Drugs
PL-18
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on CTR20232467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232467.